cancer therapeutics
Tubulis Secures $361 Million Series C to Advance Clinical-Stage Antibody-Drug Conjugates (ADCs)
Tubulis; Series C funding; antibody-drug conjugates; ADC; precision oncology; cancer therapeutics; TUB-040; TUB-030; solid tumors; clinical trials; biotech; platform optimization
NUCLIDIUM Sees Copper Isotopes as Future of Radiopharmaceuticals, Raises CHF 79M to Advance Clinical Development
NUCLIDIUM; copper isotopes; radiopharmaceuticals; Series B financing; Cu-NuriPro; NuriPro; TraceNET; oncology; theranostics; metastatic prostate cancer; neuroendocrine tumors; breast cancer; cancer diagnostics; cancer therapeutics